FilingSEC EDGAR8-K
Interpace Biosciences Announces Preliminary Q3 2026 Revenue of $10.1M to $10.4M
· SEC accepted
StagePreliminary Results
Filing content
The company announced that it expects preliminary, unaudited revenue for the third quarter of 2026 to range from $10.1 million to $10.4 million, representing a 15% to 18% year-over-year increase.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…